Omicron and its subvariants have rendered most authorized monoclonal antibody-based
treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ineffective …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Omicron variant strains encode large numbers of changes in the spike protein compared to
historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several …

Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by …

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants
of concern, including Alpha (B. 1.1. 7), Beta (B. 1.351), Gamma (P. 1), Delta (B. 1.617. 2) …

Abstract The SARS-CoV-2 B. 1.1. 529 variant (Omicron) contains 15 mutations on the
receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies …